Cristal Therapeutics, a privately-held life sciences company based in The Netherlands, has appointed Edwin Klumper as its chief medical officer.
In his new role, Klumper will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines.
He joins the pharmaceutical firm from SMS-oncology, a CRO specialising in clinical development studies in oncology, which he co-founded in 2007.
Klumper served as its chief medical officer until 2013 when he became the organisation’s interim chief executive.
Prior to this, Klumper served as vice president, marketing and sales Europe at Nabi Biopharmaceuticals and business unit director for The Netherlands at Amgen.
He also brings experience from ASTA Medica and start-up Yew Tree Pharmaceuticals where he served as its medical director.
Joost Holthuis, Cristal Therapeutics’ chief executive officer, said: “We are extremely fortunate to have Edwin joining our leadership team.
“Edwin will no doubt contribute to the already firm nanomedicine programme of CriPec docetaxel, as well as help up move forward in our efforts to develop novel proprietary nanomedicines.”